Atossa Therapeutics Explores (Z)-endoxifen as a Treatment for Duchenne Muscular Dystrophy

Atossa Therapeutics Advances Research on (Z)-endoxifen for Duchenne Muscular Dystrophy

Atossa Therapeutics, Inc. has made a significant contribution to the field of neuromuscular disease treatment with the publication of a peer-reviewed article that explores the potential of its investigational therapy, (Z)-endoxifen, for Duchenne Muscular Dystrophy (DMD) and related conditions. DMD is a severe and progressive disorder that primarily affects boys, leading to muscle degeneration and weakness. The article details how (Z)-endoxifen targets multiple disease mechanisms, including inflammation, fibrosis, and mitochondrial dysfunction, which are critical in the progression of DMD. By focusing on these aspects, Atossa aims to offer a more comprehensive treatment option for patients compared to existing therapies.

One of the key advantages of (Z)-endoxifen is its pharmacological profile, which includes the ability to modulate estrogen receptors and inhibit PKC-β1 allosterically. These properties could slow disease progression when administered alongside standard care. Unlike its predecessor, tamoxifen, (Z)-endoxifen can potentially circumvent the metabolic variability associated with the CYP2D6 enzyme, ensuring more consistent therapeutic effects. This is particularly relevant as previous studies on tamoxifen were hampered by disruptions caused by the pandemic, highlighting the need for alternative treatments like (Z)-endoxifen that offer reliable efficacy.

The article also highlights the unique pharmacokinetics of (Z)-endoxifen, noting that tissue concentrations may significantly surpass plasma levels, thereby enhancing its pharmacodynamic activity at the muscle level. This characteristic suggests that (Z)-endoxifen could effectively address not only the muscle degeneration associated with DMD but also cardiomyopathy, one of the leading causes of mortality in these patients. If proven safe and effective, (Z)-endoxifen may emerge as a scalable and accessible treatment option, providing a viable complement to high-cost genetic therapies currently available.

In addition to the publication, Atossa Therapeutics plans to present its findings at an upcoming scientific conference in November 2025. This presentation aims to further establish the rationale for (Z)-endoxifen’s multi-pathway efficacy in treating DMD and associated pathologies. The company’s commitment to advancing research in this arena underscores its focus on developing innovative therapies that can significantly improve patient outcomes in the field of neuromuscular diseases.

Overall, the exploration of (Z)-endoxifen represents a promising step forward for Atossa Therapeutics in addressing the unmet medical needs of those affected by DMD and related conditions, potentially paving the way for more effective and accessible treatments in the future.